Product Information
OXCARBAZEPINE 300 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.1667 per EA under NDC 62559022105. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on Dec 11, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559022105
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXCARBAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA078005FDA Approved
12/11/2007
TE Code
AB
On Market Since
7/15/2025
Pharmacological Classes
Price Statistics
The NADAC for OXCARBAZEPINE 300 MG TABLET has been published 42 times since Dec 17, 2025, and over the history we have for it it has declined 3.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1667 per EA |
|---|---|
| All-time high | $0.1729 (Jan 14, 2026) |
| All-time low | $0.1635 (Jul 22, 2026) |
| 52-week high | $0.1729 |
| 52-week low | $0.1635 |
| Median price | $0.1676 |
| Average price | $0.1677 |
| Largest weekly change | -1.9% (Feb 18, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxcarbazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXCARBAZEPINE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXCARBAZEPINE 300 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $0.1667 per EA (NDC 62559022105), effective Sep 30, 2026.
How has the price of OXCARBAZEPINE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXCARBAZEPINE 300 MG TABLET has declined 3.6%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for OXCARBAZEPINE 300 MG TABLET?
Since Dec 17, 2025, the NADAC for OXCARBAZEPINE 300 MG TABLET has ranged from a low of $0.1635 (Jul 22, 2026) to a high of $0.1729 (Jan 14, 2026), with a median of $0.1676 per EA.
Are there cheaper alternatives to OXCARBAZEPINE 300 MG TABLET?
9 manufacturers publish a NADAC-priced product with the same active ingredient and strength as OXCARBAZEPINE 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures OXCARBAZEPINE 300 MG TABLET?
OXCARBAZEPINE 300 MG TABLET (NDC 62559022105) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.